INTRODUCTIONOvarian tumours account for 3% of all cancers in females, being the second most common cancer of the female genital tract, next only to uterine cancer.1 They account for 30% of all cancers of the female genital tract.2 Ovarian tumours often go undetected and present at a later stage. This is due to their location, lack of early screening modalities and, lack of specific symptoms and signs suggestive of malignant nature. The advanced stage at presentation of ovarian cancers results in a low mean 5 year survival rate and a poor prognosis. 2 The ovarian tumours are highly heterogenous with a wide range of histologic patterns enumerated in the WHO classification. The gross appearances are useful to a certain extent in distinguishing the individual tumours, more so for the ABSTRACT Background: Ovarian tumours account for 3% of all cancers amongst women, being the second most common cancer of the female genital tract. The ovarian tumours are highly heterogenous with a wide range of histological patterns. Aim of current study was to study the histological patterns and the age incidence of the ovarian tumours in our institute. Methods:The present study is a prospective study conducted in the department of pathology, Andhra Medical College, from August 2011 to July 2013. Results: We received a total of 267 specimens of ovarian tumours during this period, out of which, 263 were primary and 4 were secondary tumours. Benign tumours were 209 (78.3%), borderline were 10 (3.7%) and malignant were 48 (18%) in numbers. Overall surface epithelial tumours constituted the majority of tumours accounting for 214 (80.2%) cases, followed by germ cell tumours 38 (14.2%) and sexcord stromal tumours 11 (4.1%). The single most common tumour diagnosed was serous cystadenoma. The most common malignant tumour was serous cystadenocarcinoma. The age groups affected ranged from 11-70 years. The peak age incidences for different histological types were as follows: surface epithelial tumours: 21-50 years, germ cell tumours: 21-30 years, sexcord stromal tumours: 51-60years. Benign tumours were more common in 21-40 years of age, borderline in 31-50 years and malignant tumours in 41-50 years age group. Conclusion:The results from our study were comparable with those reported in literature; however malignant serous and mucinous tumours showed a lower peak age incidence in our study. Krukenberg tumours also occurred in younger age group in our study.
Surface epithelial tumors are the most common neoplasms of the ovary. Among these, mucinous tumors accounts for 14% of ovarian tumors. Coexistence of mucinous tumor with other surface epithelial tumors is rare. We report here a rare case of mucinous cystadenoma of the ovary, with Brenner component in a 52-year-old post-menopausal woman who presented with chief complaint of mass per abdomen since one month and retention of urine since one week. Coexistence of these two tumors supports the theory of a common origin of surface epithelial tumors from coelomic or germinal epithelium, and therefore, it undergoes metaplastic change to transitional or urothelial-like morphology.
BACKGROUNDPancytopenia is one of the pathological manifestation resulting from various underlying disease processes affecting the bone marrow. Hence, bone marrow examination is the diagnostic tool to detect the underlying aetiology of pancytopenia. Pancytopenia nowadays has become a relatively common haematological entity. The underlying cause is ranging from simple drug-induced bone marrow hypoplasia, megaloblastic anaemia to fatal bone marrow aplasias and leukaemias. Thus, identification of the correct cause will help in implementing appropriate therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.